Therapeutic Targeting of Hypoxia-A2-Adenosinergic Pathway in COVID-19 Patients | Zendy

Katarina Halpin-Veszeleiova | Zendy; Stephen Hatfield | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Therapeutic Targeting of Hypoxia-A2-Adenosinergic Pathway in COVID-19 Patients

Author(s) -

Katarina Halpin-Veszeleiova,

Stephen Hatfield

Publication year - 2021

Publication title -

physiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.14

H-Index - 125

eISSN - 1548-9213

pISSN - 1548-9221

DOI - 10.1152/physiol.00010.2021

Subject(s) - adenosinergic , hypoxia (environmental) , immune system , immunology , biology , medicine , chemistry , oxygen , adenosine receptor , receptor , organic chemistry , agonist

The hypoxia-hypoxia-inducible factor (HIF)-1α-A2-adenosinergic pathway protects tissues from inflammatory damage during antipathogen immune responses. The elimination of this physiological tissue-protecting mechanism by supplemental oxygenation may contribute to the high mortality of oxygen-ventilated COVID-19 patients by exacerbating inflammatory lung damage. Restoration of this pathway with hypoxia-adenosinergic drugs may improve outcomes in these patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research